Azilsartan

Headline results for the second fiscal quarter: Revenue: JPY 1 trillion ($6.6 billion), up 4.1% Net loss: JPY 48 billion ($319 million), versus profit of JPY 61.7 billion ($410 million)Note: All changes are versus the prior-year period unless otherwise statedWhat the company said:Chief financial officer Costa Saroukos remarked “we continue to see strong performance of our growth and launch Products, which grew 13%...in the first half of the fiscal year and represent 42% of total revenue.” Saroukos noted that the second-quarter results “continued to reflect the temporary headwinds we face this fiscal year, largely from generic competition,” with the loss of exclusivity on Azilva in Japan and Vyvanse in the US.Looking ahead:Takeda now expects sales of JPY 3.98 trillion ($26.5 billion) this year, up from an earlier prediction of JPY 3.8 trillion ($25.3 billion). However, the profit forecast has been cut by nearly 36% to JPY 93 billion ($618 million) – down from an earlier estimate of JPY 142 billion ($944 million) - mainly reflecting increased impairment losses on Alofisel and Exkivity.($1 = JPY 150.390)

Headline results for the first fiscal quarter: Revenue: JPY 1058.6 billion ($7.6 billion), up 8.9% Net profit: JPY 89.4 billion ($63 million), down 14.9%Note: All changes are versus the prior-year period unless otherwise statedWhat the company said:Chief financial officer Costa Saroukos noted that “our growth and launch products continued to drive revenue growth in the first quarter. While we still anticipate headwinds affecting our business this fiscal year, largely due to generic competition, we remain confident of a return to growth in the near-term.”Notable patent expiries in 2023 include Takeda's blood pressure drug Azilva in Japan and its hyperactivity treatment Vyvanse in the US.Other results: Gastroenterology product sales: JPY 294 billion, up 8.6% Entyvio: JPY 192 billion, up 14.1% Gattex/Revestive: JPY 27.1 billion, up 23.6% Takecab/Vocinti: JPY 29.8 billion, up 7.9% Rare diseases product sales: JPY 192.6 billion, up 6.1% Rare haematology product sales: JPY 81.4 billion, up 2.8% Advate: JPY 33.8 billion, up 5.4% Rare genetics product sales: JPY 111.3 billion, up 8.5% Takhzyro: JPY 41.3 billion, up 21.4% Plasma-derived therapy/immunology sales: JPY 186.5 billion, up 31.5% Neuroscience product sales: JPY 177 billion, up 24.3% Vyvanse/Elvanse: JPY 123.2 billion, up 23.2% Oncology product sales: JPY 110.5 billion, down 6% Adcetris: JPY 27.1 billion, up 35.8% Velcade: JPY 1.8 billion, down 89% Looking ahead:Takeda said it expects eight key regulatory decisions to occur by the end of its 2023 financial year.($1 = JPY 139.886)